The clinical application for class 1.1 new drugs led by Shenyang Pharmaceutical University was accepted

Recently, new progress has been made in the development of major new drugs in Liaoning Province The application for clinical research registration of cytarabine hydrochloride valine ester and its tablet, a new drug of category 1.1, was submitted under the leadership of Shenyang Pharmaceutical University, and was accepted by the national food and drug administration Cytarabine, as a first-line clinical drug, is mainly used in the treatment of acute myeloid leukemia, acute lymphoid leukemia and lymphoma However, its poor membrane permeability and low metabolic stability make the oral bioavailability of cytarabine very low Therefore, intravenous injection must be used in clinical practice Professor He Zhonggui's research team of Shenyang Pharmaceutical University has developed valine ester hydrochloride tablets after many years of scientific research The drug greatly improved the oral bioavailability of cytarabine valine ester hydrochloride tablets Compared with the mother drug cytarabine, the oral bioavailability of cytarabine was increased from 21.8% to 60.0% It is completely suitable for oral administration It overcomes the limitations of the existing treatment of leukemia drugs, such as cytarabine, desitambin, azacytidine, etc., which can only be injected clinically, but not orally, It can greatly improve the indications of clinical patients, but also reduce the high treatment costs of patients After the industrialization of products, it will have broad economic and social benefits It is understood that the drug is the first in China, and has obtained the key support of national science and technology major special project of major new drug creation - comprehensive new drug platform, and has obtained two national invention patents.